Division of Oncology
in the Department of Medicine
Welcome to the Division of Oncology, a center of excellence in patient care, medical education, and state-of-the-art research. Cancer is a major public health problem and it is also an exciting challenge for discovery and innovation.
Message from the Chief
A welcome message from the the Division of Oncology's chief, Dr. George W. Sledge Jr.
The Division of Oncology is seeking qualified faculty for several open positions. Successful applicants must hold an MD or MD/PhD degree and be board-certified or board-eligible in Medical Oncology, and have a history of significant peer-reviewed funding.
- To engage in research to create the future of cancer care
- To provide the best in care for cancer patients
- To train physicians for careers in academic medicine and research
IN THE NEWS
- Watch NBC for an update on Dr. Ronald Levy's upcoming cancer vaccine study
- Listen to Science Friday for an interview about the Levy lab's cancer vaccine discovery published in Science Translational Medicine on 1/31/18
- During a recent TedxPaloAlto talk, Idit Sagiv-Barfi, MD, PHD, an instructor of oncology, discussed the future of cancer vaccines.
Dr. Bui is a new Clinical Assistant Professor in the Clinician Educator line. Nam joins us from UCSD, where he completed his Hematology/Oncology fellowship. Prior to fellowship, he did his Internal Medicine residency at Stanford, so we welcome him back. He is splitting his time between our Phase I and Sarcoma groups, in both a patient care and clinical research capacity. In addition to his clinical interests, he has a strong background in medical informatics, and draws enjoyment from pouring over the TCGA database for clues as to novel therapeutic targets for specific malignancies. We’re delighted to have him join our ranks.
Dr. Khodadoust (M.D. Ph.D.) joins us an Assistant Professor (MCL) specializing in the study and treatment of lymphoma; previously he did his fellowship with us here at Stanford. His clinical work focuses on cutaneous T Cell lymphoma, where he works in conjunction with our excellent Dermatology group on this difficult disease. Michael is also a superb laboratory researcher, having (within the past year) had a first-author publication in Nature, and received an NIH K award for his upcoming studies. He will be a splendid addition to our already-strong lymphoma team.
Dr. Itakura, also a former Stanford Oncology fellow, joins our group as an Assistant Professor in the MCL line, joining our breast cancer group. In addition to her cancer training, Dr. Itakura recently received a PhD in Biomedical Informatics. Her research in this area involves the fascinating new discipline of radiogenomics, and is funded by an NIH K01 award. Her PhD work resulted in a wonderful paper in Science Translational Medicine and has led to ongoing studies involving radiogenomics in multiple diseases. She is a master of cross-platform data analyses, which in a “Big Data” era should represent a substantial addition to our research efforts. We are pleased to have her in the Stanford Oncology family.
We welcome Dr. John, PhD, to the faculty of the Division of Oncology. Dr. John comes to us from the Cancer Prevention Institute of California, where she has had a long and distinguished career as a cancer epidemiologist, with over 300 peer-reviewed publications. Her work has focused on the epidemiology of breast and prostate cancer in racial and ethnic minority populations, investigating cancer disparities in incidence and survival. For the past 3 years she has served as co-leader of the Population Sciences Program for the Stanford Cancer Institute. She has also been a regular collaborator with several members of our division, so we are delighted to have her join our Oncology family.
Sigurdis Haraldsdottir, MD (assistant professor, Hematology/Oncology), is a recent (October 2015) newcomer to the Department of Medicine faculty. She is a native of Iceland, a fact that colors her professional interests as well as the ways she chooses to spend her free time.